Bombay Oxygen (509470)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹25,850, Bombay Oxygen trades at a meaningful discount to its book value of ₹35,127 per share. P/B of 0.74 is the kind of margin of safety Graham would circle. But cheap is not the same as attractive. The business earns only 3.01% ROE and 3.89% ROCE. That means the underlying assets are not being converted into shareholder value. The latest quarter shows sales of ₹10 Cr and net profit of ₹9 Cr. While the reported sales growth of 156.15% and profit growth of 159.17% are headline-grabbing, the absolute figures are small. A P/E of 18.26 is not obviously cheap when earnings are so dependent on a low base. The PEG of 0.12 is meaningless when growth is lumpy, not durable. The Piotroski F-score of 7/9 is a positive sign for balance-sheet health, but the dividend yield of 0.18% tells me this is not an income stock. I am bothered by the lack of promoter holding data and the N/A debt/equity figure. As an NBFC, asset quality and leverage are critical; without those, one is investing blind. What I see is an asset play: shareholders own a stated asset base of ₹35,127 per share, but the market pays only ₹25,850. The gap exists because the assets earn little. For a value investor, this can be a good risk-reward only if there is a catalyst—a buyback, a special dividend, an asset sale, or a fundamental improvement in ROE. I would not buy just because it is below book value. I would need evidence that management is willing and able to unlock value. Until then, Bombay Oxygen is a classic asset situation, but not a compounder.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer